JOSE MANUEL
BAENA CAÑADA
Profesor asociado de Ciencias de la Salud
Universidade da Coruña
La Coruña, EspañaPublicaciones en colaboración con investigadores/as de Universidade da Coruña (8)
2020
-
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 3, pp. 203-213
-
Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study
Scientific Reports, Vol. 10, Núm. 1
-
Serum phospholipids fatty acids and breast cancer risk by pathological subtype
Nutrients, Vol. 12, Núm. 10, pp. 1-18
2019
-
Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study
Scientific Reports, Vol. 9, Núm. 1
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
2018
-
Psychological distress and health-related quality of life in women recently diagnosed with breast cancer in the Epi-GEICAM study
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii85
2015
-
Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study
Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795
-
Lower breast cancer risk among women following the World Cancer Research Fund and American Institute for Cancer Research lifestyle recommendations: Epigeicam case-control study
PLoS ONE, Vol. 10, Núm. 5